Fragment 176-191 vs AOD-9604: The Fat-Loss Peptide Comparison

Fragment 176-191 and AOD-9604 refer to the same molecule — the 16-amino acid C-terminal fragment of human growth hormone (residues 176-191). "Fragment 176-191" refers to the residue positions; "AOD-9604" was the development code from Metabolic Pharmaceuticals (Australia). They are identical compounds.

Origin: Isolating hGH's Lipolytic Domain

Human growth hormone (hGH) has two functional domains: the N-terminal domain mediating growth promotion and IGF-1 induction, and the C-terminal domain (residues 177-191) mediating direct lipolysis. The goal in developing Fragment 176-191 was isolating fat-mobilising activity without growth-promoting, mitogenic, or insulin-resistance-promoting effects.

AOD-9604 has essentially zero affinity for the IGF-1 receptor, insulin receptor, and full-length GH receptor — confirming no growth or diabetogenic effects.

Mechanism: β3-Adrenergic Receptor Stimulation

The lipolytic mechanism does not involve the full-length GH receptor. Evidence points to β3-adrenergic receptor (β3-AR) activation in adipocytes — the same receptor targeted by emerging anti-obesity drugs. β3-AR activation stimulates hormone-sensitive lipase (HSL) and adipocyte triglyceride lipase (ATGL) → lipolysis.

In *ob/ob* obese mice at 1 mg/kg/day subcutaneously for 6 weeks:

• Total body fat: reduced 25-50% vs saline controls
• Lean mass: unchanged (no anabolic effect)
• Fasting glucose and insulin: unchanged (no diabetogenic effect)
• IGF-1 levels: unchanged (no GH-axis activation)

Clinical Development Failure

AOD-9604 advanced through Phase 3 clinical trials for obesity in humans (2000-2003). In 24-week trials at several doses (1, 5, 10 mg/day SC), no statistically significant difference in body weight or fat mass was found vs placebo at any dose.

The failure was attributed to poor translation of rodent β3-AR pharmacology to humans — human adipose β3-AR expression and coupling efficiency is significantly lower than in rodent models.

Post-Failure Research Directions

Despite clinical obesity failure, AOD-9604 research continues for:

• Cartilage repair: Phase 2a evidence of promoting cartilage proteoglycan synthesis via TGF-β pathways
• Metabolic research tool: Useful for studying β3-AR pharmacology in adipose without confounding hGH anabolic effects

The contrast with Semaglutide's clinical success illustrates the central appetite suppression approach dramatically outperforming peripheral adipocyte lipolysis in human obesity pharmacology.

AOD-9604 is a research compound. Clinical development for obesity was discontinued. This content is educational only.

<!-- deep-links-v1 -->

Related Metabolic and Fat-Targeting Peptides

Beyond the GH-fragment approach, several other compounds target adipose tissue through distinct mechanisms. Adipotide (FTPP) induces apoptosis in white adipocyte vasculature, representing a pro-apoptotic rather than receptor-agonist approach to fat loss. AICAR activates AMPK kinase to produce exercise-mimetic metabolic shifts independent of GH axis signaling. Retatrutide, through GLP-1R/GIPR/GcgR triple agonism, achieves fat loss through incretin and thermogenic pathways. Cagrilintide reduces caloric intake through the amylin receptor, providing complementary satiety to GH fragment-based lipolysis. Suprefort supports pancreatic beta-cell health in metabolic disorder models. Pancragen is a pancreatic bioregulator that addresses the exocrine-endocrine pancreatic balance in metabolic syndrome research.